Therapeutic Advances in Psychopharmacology

Papers
(The H4-Index of Therapeutic Advances in Psychopharmacology is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Prevalence and predictors of inappropriate prescribing in outpatients with severe mental illness105
Relationship between resilience and mental health among COVID-19 bereaved people: the mediating role of dual process coping56
Biological markers of treatment response to serotonergic psychedelic therapies: a systematic review46
History repeating: guidelines to address common problems in psychedelic science39
Comment on: History repeating: guidelines to address common problems in psychedelic science27
The missing link? Pharmacists’ perspectives on discontinuation of long-term antidepressants: a qualitative study26
A rapid clinical response to etifoxine in treatment-resistant obsessive-compulsive disorder: a case report of a patient with comorbid bipolar disorder26
Disrupted emotion regulation and spontaneous neural activity in panic disorder: a resting-state fMRI study25
Incidence of hyperthyroidism in patients with bipolar or schizoaffective disorder with or without lithium: 21-year follow-up from the LiSIE retrospective cohort study24
Psychotropic medications versus non-pharmacologic approaches for managing behavioural and psychological symptoms in Australian aged care residents with dementia: general practitioners’ and physicians’23
Adult psychiatrists’ views on clozapine prescribing for schizophrenia in Germany—an online survey22
Corrigendum to “Managing medical and psychiatric multimorbidity in older patients”20
Reasons for discontinuing and restarting lithium multiple times: a case-register study based on the South London and Maudsley NHS Foundation Trust Clinical Record Interactive Search system19
Plain Language Summary of Publication: A comparison of once-monthly and once-every-2-months injectable formulations of aripiprazole in people with schizophrenia17
Sympathetic activation but not dissociation linked to ketamine’s sustained antidepressant effect17
A description of antipsychotic prescribing patterns on the inpatient behavioral health setting: a multicenter cross-sectional analysis17
0.22489285469055